Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.

Leukemia - 1 Sept 2017

Rinke J, Müller J P, Blaess M F, Chase A, Meggendorfer M, Schäfer V, Winkelmann N, Haferlach C, Cross N C P, Hochhaus A, Ernst T

Abstract excerpt

Mutations in the epigenetic regulator gene EZH2 are frequently observed in patients with myelodysplastic/myeloproliferative neoplasms (MDS/MPN; 10-13%) and are associated with a poor outcome. To gain more insight into EZH2 pathology, we sought to genetically characterize a cohort of 41 EZH2-mutated MDS/MPN patients using targeted deep next-generation sequencing (NGS), colony-forming progenitor assays and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Cell Line

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Enhancer of Zeste Homolog 2 Protein

Share to Gene Expression Regulation, Leukemic

Share to High-Throughput Nucleotide Sequencing

Share to Leukemia

Share to Mutation

Source

Identifiers

PMID: 28626218
DOI: 10.1038/leu.2017.190

Genes

ASXL1
CXXC5
ETS1
RUNX1
TET2
VAV3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.PMID 28626218Read ↗

Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.Semantic proximity Read ↗

Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients.Semantic proximity Read ↗

Update on cytogenetic and molecular changes in myelodysplastic syndromes.Semantic proximity Read ↗

The epigenomics revolution in myelodysplasia: a clinico-pathological perspective.Semantic proximity Read ↗

Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.Semantic proximity Read ↗

Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent mannerSemantic proximity Read ↗

EZH2 in Myeloid Malignancies.Semantic proximity Read ↗

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutationsSemantic proximity Read ↗

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.Semantic proximity Read ↗

Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.Semantic proximity Read ↗

The role of histone methyltransferase EZH2 in myelodysplastic syndromes.Semantic proximity Read ↗

Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic SyndromesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.